* Osteotech Inc., of Shrewsbury, N.J., said studies of its bonedemineralization process show that it inactivated HIV, hepatitis andother viruses in bone transplants. The findings, according to thecompany, demonstrate that the process reduces the risk ofcontracting HIV from donor bone and connective tissues to lessthan one chance in 2.8 billion.* Zynaxis Inc., of Malvern, Pa., signed an agreement with SupragenInc., of Lakewood, Colo., to develop drugs based on the former'sZyn-Linker drug delivery technology and the latter's superantigens,which are proteins that activate T cells involved in autoimmune,inflammatory and infectious diseases.* Chiron Corp., of Emeryville, Calif., said the FDA has approvedAredia for treatment of moderate to severe Paget's disease. Thedrug, pamidronate disodium, is manufactured by Switzerland-basedCiba-Geigy Corp. and marketing in the U.S. by Chiron. Arediaalready is on the market for hypercalcemia associated withmalignancy.* PerSeptive BioSystems Inc., of Cambridge, Mass., has amendedits patent infringement lawsuit against Pharmacia AB, of Sweden,and Sepracor Inc. and BioSepra Inc., both of Marlborough, Mass.,to include alleged violation of PerSeptive's Modular SurfaceChemistry patent by BioSepra. The patent infringement suit wasfirst filed by PerSeptive in October 1993 against Sepracor andPharmacia. BioSepra, a subsidiary of Sepracor, was added as adefendant in May.* Procept Inc., of Cambridge, Mass., said Gerhard Wagner, ofHarvard University Medical School, has identified the three-dimensional structure of the protein CD2, a receptor that mediatesbetween T cells and antigen-presenting cells in the immune system.* ESCAgenetics Corp., of San Carlos, Calif., has signed anagreement with Kalyani Agro Corp. Pvt., of Pune, India, to producehybrid potato seed tubers in India. The collaboration could yield thefirst sales of the potatoes by October 1995.
(c) 1997 American Health Consultants. All rights reserved.